{
  "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
  "docSlug": "560176b410a72a6b2e67af5dd2a20758",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 33,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/24",
  "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
  "deckJsonHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56.json",
  "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.56,
        "w": 0.44,
        "x": 0.02,
        "y": 0.275
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0dbbb320-2ff0-40a4-ace6-0aedc96d7a89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.42,
        "x": 0.54,
        "y": 0.285
      },
      "kind": "list",
      "text": "Novel combination therapy candidate of approved products optimized for PK and synergistic effects to address ALS and potentially other disease targets",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08558f02-8441-4404-850d-33b4f8f3eaaf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.42,
        "x": 0.54,
        "y": 0.445
      },
      "kind": "list",
      "text": "Robust clinical efficacy and excellent safety profile observed from ALS Phase 2a and 2b clinical studies. 37% reduction in ALSFRS-R (p=0.03) in phase 2b study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b278d76-4740-49da-b8c3-da3d2fbc2263",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.54,
        "y": 0.735
      },
      "kind": "list",
      "text": "Patent coverage for novel formulation, method & combination (until 2038)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "968e6792-0b29-4674-8dde-3dabc37cd09a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.54,
        "y": 0.605
      },
      "kind": "list",
      "text": "Expedited and de-risked regulatory pathway (orphan drug designation / 505(b)2 pathway)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aae67604-143e-46ad-a628-b45f6662e010",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.89,
        "x": 0.02,
        "y": 0.11
      },
      "kind": "title",
      "text": "PrimeC: Strong Clinical and Commercial Potential",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01b47394-9b9b-44d5-9fe6-110b7d7ddff4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 6,
      "beatId": "34d973c9-414c-4e7d-9b2b-216172775550",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 24,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "e681d414-7700-4a5b-99a5-b22bec923cbe",
      "evidence": "The document mentions the potential for PrimeC in Alzheimer's disease, highlighting its broad therapeutic potential.",
      "position": 2,
      "objective": "What is the potential for PrimeC in other neurodegenerative diseases?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}